Central nervous system disorders (CNS) make up more than 600 conditions that affect over 2 billion people worldwide with an estimated economic burden of more than $2 trillion in the US and EU alone. Due to this unmet medical need and financial burden, the neurotechnology sector has seen important increases in investment over the last decade. Now in its fourth year, the European Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software, and diagnostics for the brain and nervous system. This event will bring together C-level executives, investors, and entrepreneurs to address challenges in investing, funding, partnering, and development of new treatments and diagnostics for the brain and nervous system. Overall, this event will provide delegates with a forum to learn, network, and shape the future of their organization and the industry.

FINAL AGENDA


TUESDAY, 3 OCTOBER

7:30 Conference Registration


8:30 Welcome and State of the Industry Keynote
Alison Fenney, Executive Director, Neurotechnology Industry Organization

KEYNOTE PRESENTATION: From Concept to Clinic: Neurotechnology Translation Today
John Donoghue, Ph.D., Founding Director, Wyss Center

9:00 Panel Discussion: Investing in Neurotech
A diverse panel of private, public and strategic investors will discuss what it takes to get a neurotech company funded. The benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology will be addressed. Delegates will learn more about today's deal terms and valuations as well as exit strategies. Finally, the neurotech industry will be evaluated in comparison with other industries.

Panelists:
Daniel Bertholet, Senior Investment Director, Endeavour Vision
Jasper Bos, Ph.D., Vice President, Head, Healthcare Fund, Merck Ventures
Sara Nunez Garcia, Principal, Sofinnova
Einat Zisman, Ph.D., CEO, FutuRx Ltd.

10:00 Coffee Break


10:45 Treatment for Alzheimer's and Cognitive Disorders 
Alzheimer’s disease and related dementias affect over 46 million people worldwide, with an estimated cost of $818 billion. Ongoing efforts to develop disease modifying therapies have been plagued with failures. This session will address new avenues being pursued to address the growing global need, novel diagnostics for early detection, and non-pharmacological options in development.

Alzheon, Inc. – A Precision Medicine Approach to Alzheimer’s Disease

Martin Tolar, M.D., Ph.D., Founder, President & CEO, Alzheon, Inc.

New Hope for Alzheimer's Patients

Charles Stacey, M.D., President and CEO, Accera

O-Glcnacase Inhibitor ASN120290 as Anti-Tau Drug Candidate for Alzheimer’s Disease and Other Tauopathies

Dirk Beher, Ph.D., CEO, Asceneuron SA

Talk Title to be Announced

Carlos Buesa, CEO, Oryzon

Developing Anti-Pglu-Abeta Therapies – the Differentiated Abeta Approach to Treat Alzheimer’s Disease

Hendrik Liebers, Dr. Rer. Med., CFO, Probiodrug AG


11:45 Emerging Company Showcase I

This showcase allows neurotechnology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Companies presenting in this session are addressing unmet medical needs, were founded no earlier than 2012, and are actively seeking funding.

Now Accepting Submissions 

12:15 Networking Luncheon

14:15 Panel Discussion: Internal & External Research and Development

Big pharma, medtech, and biotech companies collaborate with smaller companies and academic institutions on a variety of projects. This panel discussion will address opportunities for research and development collaborations with academic groups, research institutes, and platform companies. Delegates will learn how to spot opportunities, current areas of interest, and how to focus internal and external resources.

Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry Organization
Panelists:
Pierandrea Muglia, Vice President, Neuroscience Discovery, UCB Pharma
Jeff Erb, Senior Director, Strategy, Business Development and Alliance Management, Medtronic
Additional Panelists to be Announced

15:15 Refreshment Break with Exhibit Viewing


16:00 Frontiers in Neurotechnology 
This session includes companies on the cutting edge of neuroscience. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Companies in this session will showcase their innovative next-generation products and how they are addressing unmet needs in neurotech.

Talk Title to be Announced

Ann Bunnenberg, Ph.D., JD, Chief Operating Officer and President, Electrical Geodesics, Inc.

Talk Title to be Announced

Beth Rosellini, Vice President, Clinical Affairs, Nexeon Medsystems

Nexstim - Targeting a Paradigm Shift in Stroke Rehabilitation

Martin Jamieson, Chairman of the Board, CEO, Nexstim Plc

How to Revolutionize Treatments for Brain Cancer and Neurologic Conditions

Frederic Sottelini, CEO, CarThera


17:00 Emerging Company Showcase II

This showcase allows neurotechnology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Companies presenting in this session are addressing unmet medical needs, were founded no earlier than 2012, and are actively seeking funding.

Now Accepting Submissions 

17:30 Welcome Reception with Exhibit Viewing

18:30 Close of Day


WEDNESDAY, 4 OCTOBER

8:00 Conference Registration

8:30 KEYNOTE PRESENTATION: Towards a Major Service-Based Research Infrastructure for Brain Research

Christoph Ebell, Executive Director, Human Brain Project

9:30 Coffee Break with Exhibit Viewing


10:15 Bench to Bedside, Profiling the Wyss Center Panel Discussion
This session will feature discussions around the funding and de-risking of early neurotech concepts, offer advice on how to attract investors, and give tips on how to avoid common pitfalls on the journey of a new concept from lab bench to the clinic.

Moderator: Tracy Laabs, Ph.D., Assistant Director, Wyss Center
Speakers:
Claude Clément, CTO, Wyss Center
Daniel O’Connell, MBA, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.
Hunter Peckham, Ph.D., Associate Director, Technology Transfer, Cleveland FES Center; Distinguished University Professor, Donnell Institute Professor of Biomedical Engineering, and Professor of Orthopaedics; Executive Director, Institute for Functional Restoration, School of Medicine, Case Western Reserve University; Senior Research Career Scientist, and Biomedical Engineer, Louis Stokes Cleveland VA Medical Center
Claudio Pollo, M.D., Head, Functional Neurosurgery, University Hospital Berne, Switzerland

11:15 Panel Discussion: Partnering and Licensing in Neurotech
Neurology is projected to be medtech’s fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. This panel will address current trends in strategic alliances and inlicensing, priority indications and requirements for licensing deals, and companies active in deal-making.

Panelists:
Maciek Drozdz, Principal, Venture Investments, J&J Development Corporation
Charlie Bailey, Ph.D., Global Head, Neuroscience, Business Development & Licensing, Novartis
Additional Panelists to be Announced

12:15 Networking Luncheon


13:45 Next-Generation Psychiatry 
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a substantial portion of the neurotech market. This session will focus on the most promising next-generation treatments as well as devices and diagnostics to change the treatment landscape.

Talk Title to be Announced

Adrian Attard Trevisan, Ph.D., Co-Founder/Director, Umana Medical Technologies

RP5063, a Novel Dopamine-Serotonin Stabilizer for Treating Schizophrenia and Schizoaffective Disorders

Laxminarayan Bhat, Founder, President & CEO, Reviva Pharmaceuticals Inc.

Additional Speakers to be Announced


14:15 Strategies in CNS Drug Development (Sponsorship opportunities available)
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Moderator: Carla M. Lema Tome, MBA, Ph.D., INC Research

15:45 Networking Refreshment Break


16:00 Parkinson's and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” periods especially as the disease progresses. 2017 has seen spike drug approvals in movement disorders, with strong pipelines for symptomatic treatment in development. Hear from companies developing assets and platforms to treat Parkinson’s, ALS, and orphan motor disorders.

Achieve Immunotherapy Candidates PD01A, PD03A Targeting Alpha Synuclein in Parkinson´s Patients

Oliver Siegel, CEO, AFFiRiS AG

Partnering in Parkinson’s Disease and Movement Disorders from Pharma’s Perspective

Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Holdings America, Inc.

Opening New Therapeutic Options Against Multiple Sclerosis and Other Autoimmune Diseases

Jesús Martin-Garcia, Chairman and CEO, GeNeuro

A New Drug Discovery Paradigm Pioneered by Pharnext: PLEOTHERAPYTM

Xavier Paoli, Chief Commercial Officer; VP R&D Operations, Pharnext

Talk Title to be Announced

Michael Almstetter, CEO, Origenis GmbH


17:00 Close of Conference

Demographics

NIO

 

 

View All Sponsors

 

View_Media 

FreeMindLogo


Neurotech